[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
August 1965

Urate Diuretic Therapy in Chronic Gout: A Comparative Study of Probenecid and Sulfinpyrazone

Author Affiliations


From the Department of Medicine, University of Colorado School of Medicine and the Veterans Administration Hospital. Geigy Arthritis Research Fellow and presently at Johns Hopkins Hospital, Baltimore (Dr. Velayos), and Associate Professor of Medicine, University of Colorado School of Medicine (Dr. Smyth).

Arch Intern Med. 1965;116(2):212-219. doi:10.1001/archinte.1965.03870020052012

HIPPOCRATES in the fourth century BC stated that once a gouty subject developed tophi in the joints he was beyond the power of medicine.1 This dictum of the Father of Medicine held true until the most recent times. The development of effective uricosuric agents marked the beginning of a new era in the treatment of the tophaceous stage of this ancient illness, and since then there has been rapid and steady progress in the control of this disease. By the reduction of the urate stores and the maintenance of the serum urate concentration at or near normal, it has been clearly demonstrated that acute attacks of gouty arthritis decrease or cease, tophi decrease or disappear, joint function may be improved.2-7,23 These events have stimulated a search for the most effective urate diuretic agent capable of long-term use. The purpose of this report is to present further evidence